June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Results of focal photocoagulation in polypoidal choroidal vasculopathy patients from a Dutch referral center
Author Affiliations & Notes
  • Marc J. Sirks
    Ophthalmology, Amsterdam UMC Locatie AMC, Amsterdam, North Holland, Netherlands
  • Helena Margaret Anthonia Feenstra
    Ophthalmology, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • Florentine R. de Vries
    Ophthalmology, Alrijne Ziekenhuis, Leiden, Zuid-Holland, Netherlands
  • Greet Dijkman
    Ophthalmology, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • Camiel J F Boon
    Ophthalmology, Amsterdam UMC Locatie AMC, Amsterdam, North Holland, Netherlands
    Ophthalmology, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • Elon H.C. van Dijk
    Ophthalmology, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • Footnotes
    Commercial Relationships   Marc Sirks None; Helena Feenstra None; Florentine de Vries None; Greet Dijkman None; Camiel Boon None; Elon van Dijk None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3768 – F0189. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marc J. Sirks, Helena Margaret Anthonia Feenstra, Florentine R. de Vries, Greet Dijkman, Camiel J F Boon, Elon H.C. van Dijk; Results of focal photocoagulation in polypoidal choroidal vasculopathy patients from a Dutch referral center. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3768 – F0189.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report the outcomes of focal thermal laser photocoagulation in polypoidal choroidal vasculopathy (PCV) patients from a Dutch referral center.

Methods : We describe a retrospective series of 24 eyes with indocyanine green angiography (ICGA)-proven PCV who had received focal laser photocoagulation. Inclusion criteria were: 1) the presence of either one or a cluster of extrafoveal polyps in the early phase of ICGA, with or without a co-existing neovascular network, 2) the presence of visual symptoms, and 3) the performance of focal laser photocoagulation, but no intravitreal injections with anti-vascular endothelial growth factor (VEGF) medication for at least 6 weeks before laser photocoagulation.

Results : Twenty-four eyes of 22 patients were included. The mean age of patients was 72 years, with a female predominance (82%). The most common clinical features at presentation were exudates (88%), either serous or hemorrhagic pigment epithelial detachments (PEDs) (58%), and (sub)retinal hemorrhages (46%). During the mean total follow-up of more than 2 years, focal laser photocoagulation was applied once in 14 eyes (58%), and multiple times in 10 eyes (42%). Three months after laser photocoagulation, exudates were only seen in 17% of cases, serous or hemorrhagic PEDs in 4%, and hemorrhages in 4%. Over the first 3 months following laser photocoagulation, best-corrected visual acuity (BCVA) in Snellen improved 2 lines or more in 10 eyes (42%), decreased 2 lines or more in 4 eyes (16%), and remained stable (≤1 line change) in 10 eyes (42%). Only 5 remaining polyps were observed at the visit at 3 months after treatment and only 1 polyp was seen at 1 year after treatment. During the mean follow-up of 27 months, 7 of the 24 eyes (29%) had a polyp recurrence.

Conclusions : We observed a marked decrease of exudates, PEDs, and subretinal hemorrhages after focal laser photocoagulation in eyes with extrafoveal PCV, with a recurrence of polyps in only 25% of our cases, with a mean follow-up of 2 years. Visual acuity improved or stabilized in the majority of eyes. Monotherapy with focal laser photocoagulation may therefore still be a treatment option in PCV patients for whom photodynamic therapy or anti-VEGF medication is not available or for whom an intravitreal anti-VEGF injections treatment regimen is too intensive.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×